Announcements Trials

Browse Landscape

Phase

Status

Recruiting 4 Active not recruiting 2 Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 1499 Cisplatin 1435 Paclitaxel 1340 Radiotherapy 1310 Carboplatin 1267 Gemcitabine 1226 Docetaxel 1133 Bevacizumab 1070 Fluorouracil 906 Doxorubicin 805 Dexamethasone 755 Rituximab 744 Capecitabine 735 Oxaliplatin 709 pembrolizumab 700 Etoposide 679 Irinotecan 639 Filgrastim 624 Cytarabine 587 Nivolumab 586 Leucovorin 583 Vincristine 517 Cetuximab 479 Prednisone 478 Bortezomib 474 Trastuzumab 468 Erlotinib Hydrochloride 467 Surveys and Questionnaires 460 Methotrexate 444 Lenalidomide 436

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × azeliragon × Clear all

NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡